Enhancing the Breadth and Efficacy of Therapeutic Vaccines for Breast Cancer

Abstract

The focus of the Spellman/Gray work group over the past year has been upon the generation of materials, tools, and data for the purpose of aiding and supporting the research and findings of the entire multi-team collaboration endeavoring to identify antigenic targets of breast cancer-infiltrating T cells. During this time, our group generated the breast cancer cell line lysates necessary to provide uniform sources of major antigens associated with each tumor subtype for stimulation of T cell clones isolated by our collaborators. An analytical pipeline was also developed to perform in silico epitope prediction using RNAseq data as input; the data from which will contribute to the understanding of expressed tumor-associated protein-encoding transcripts. For several of our breast cancer cell lines, MHC-I-bound epitopes were identified via immunoprecipitation and mass spectrometry to assist characterization and prioritization of antigenic targets. Finally, a small molecule drug screen was carried out on breast cancer cell lines and normal T cell clones to determine each drug s potential to combine with T cell-based therapies in promotion of apoptosis via tumor cell signaling pathways and CTL-mediated killing.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2012
Accession Number
ADA569514

Entities

People

  • Dmitri Rosanov
  • Kami Chiotti
  • Paul Spellman

Organizations

  • Oregon Health & Science University

Tags

DTIC Thesaurus Topics

  • Apoptosis
  • Body Fluids
  • Breast Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Cultured Cells
  • Lymphocytes
  • Mass Spectrometry
  • Materials
  • Molecules
  • Neoplasms
  • Proteins
  • Small Molecules
  • Spectrometry

Fields of Study

  • Biology

Readers

  • Immunology
  • Molecular Genetics
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech